Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 12, 2025Current Hematologic Malignancy ReportsOpen Access

Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms

View Full Paper
Ask AI
Bookmark
Share

Authors

PBPrithviraj BoseZXZhijian XiaoHHHans Carl Hasselbalch

Discussion

Loading...

Member takes

Overview

Symposium reveals insights on molecular profiling and therapeutic strategies in myeloproliferative neoplasms, highlighting real-world data implications.

Key Points

  • Molecular profiling enhances risk stratification and therapeutic decision-making in myeloproliferative neoplasms.
  • Ropeginterferon alfa-2b demonstrated durable efficacy, yielding rapid reductions in JAK2V617F allele burden.
  • Combination therapies with ruxolitinib and other agents showed promise for improved treatment outcomes.
  • Regional studies contributed valuable real-world evidence, shaping a global approach to managing MPNs.

Cite This Study

Bose et al. (2025) studied this question.

synapsesocial.com/papers/689a02afe6551bb0af8cbea3https://doi.org/10.1007/s11899-025-00752-3
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Treatment landscape and outcome of myeloproliferative neoplasms in asia: Interim analysis of the Asian myeloproliferative neoplasm registry2025
  2. 2[A new era in the treatment of myeloproliferative neoplasms].2025
  3. 3Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress2026
  4. 4Efficacy and safety of pegylated interferon alfa-2b in myeloproliferative neoplasms: A multicenter retrospective study of 210 patients2025
  5. 5Myelodysplastic/myeloproliferative overlap neoplasms: Clinicopathological features, treatment strategies, and outcomes — a UK multicentre cohort Study2025